Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2023-05-09 Annual Report
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Approval of the Audited Financial Statements for the quarter and year ended March 31, 2023 and recommend final dividend @ 200% i.e. Rs. 4/- per equity share of the face value of Rs. 2/- ....
Annual Report Classification · 95% confidence The document is a detailed communication from Lupin Limited to stock exchanges and regulatory bodies, referencing compliance with SEBI Listing Regulations. It includes audited standalone and consolidated financial results for the quarter and year ended March 31, 2023, along with auditors' reports dated May 9, 2023. The document contains comprehensive financial tables with revenue, expenses, profit, tax, and other financial metrics for multiple periods, indicating it is a full financial report rather than a brief announcement or certification. The presence of audited financial statements and auditors' opinions confirms this is a formal annual financial report. Therefore, the document fits the definition of an Annual Report (10-K equivalent).
2023-05-09 English
Dividend
Annual Report Classification · 95% confidence The document is a detailed communication from Lupin Limited to stock exchanges regarding the approval and publication of audited standalone and consolidated financial results for the quarter and year ended March 31, 2023. It references compliance with SEBI Listing Regulations, includes financial tables with comprehensive data, and mentions auditors' reports with unmodified opinions. The document contains actual financial statements and analysis for the fiscal year, not just an announcement or summary. Therefore, it is a full Annual Report type filing covering the company's yearly financial performance.
2023-05-09 English
Audited Financial Statements for the quarter and year ended March 31, 2023.
Annual Report Classification · 95% confidence The document is a detailed communication from Lupin Limited to stock exchanges and regulatory bodies, referencing compliance with SEBI Listing Regulations. It includes audited standalone and consolidated financial results for the quarter and year ended March 31, 2023, along with auditors' reports dated May 9, 2023. The document contains comprehensive financial data such as revenue, expenses, profit before tax, tax expenses, and net profit for the specified periods. It also mentions dividend recommendations subject to shareholder approval. The presence of full financial statements and auditors' opinions indicates this is the official annual financial report. The document length (15,000 characters) and detailed financial tables confirm it is not merely an announcement or certification. Therefore, the filing type corresponds to an Annual Report (10-K equivalent) for the fiscal year ending March 31, 2023.
2023-05-09 English
Financial Result Updates
Annual Report Classification · 95% confidence The document is a detailed communication from Lupin Limited to stock exchanges regarding the approval and publication of audited standalone and consolidated financial results for the quarter and year ended March 31, 2023. It references compliance with SEBI Listing Regulations, includes financial tables with comprehensive data, and mentions auditors' reports with unmodified opinions. The document contains actual financial statements and analysis for the fiscal year, not just an announcement or summary. Therefore, it is a full Annual Report or equivalent annual financial results filing rather than a brief announcement or certification. Given the detailed financial data and the annual period covered, the appropriate classification is Annual Report (10-K).
2023-05-09 English
Acquisition of French Pharmaceutical Company Medisol.
Capital/Financing Update Classification · 95% confidence The document is a press release announcing Lupin Limited's definitive agreement to acquire the entire share capital of the French pharmaceutical company Medisol, subject to regulatory approval. It is addressed to stock exchanges and references compliance with SEBI Listing Regulations. The content focuses on the acquisition announcement, company background, and strategic rationale. There are no financial statements, detailed financial analysis, or regulatory filings such as merger proxy statements or tender offers. The document is not a full merger filing (MA) or a tender offer but an announcement of a transaction. It is not a report or detailed presentation but a formal disclosure press release. Therefore, the most appropriate classification is Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes including acquisitions.
2023-05-05 English
Press Release
M&A Activity Classification · 95% confidence The document is a press release announcing Lupin Limited's definitive agreement to acquire the French pharmaceutical company Medisol. It includes details about the acquisition, company backgrounds, and strategic comments from executives. There are no financial statements, detailed financial performance data, or regulatory filings such as 10-K or interim reports. The document is a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which typically covers material events or corporate actions. This fits the category of M&A Activity (TAR) as it announces a merger/acquisition event. The document length (5780 characters) and content confirm it is the announcement itself, not a brief notification or a report publication announcement. Therefore, the correct classification is TAR with high confidence.
2023-05-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.